DOCUMENT ELECTRONICALLY FILED UNITED STATES DISTRICT COURT | DOC #: SOUTHERN DISTRICT OF NEW YORK DATE FILED:5/4/2023 OPINION AND ORDER ON MOTION IN RE LIFETRADE LITIGATION: FOR PROTECTIVE ORDER 17-CV-2987 (JPO)(KHP)
+--+ ----X KATHARINE H. PARKER, UNITED STATES MAGISTRATE JUDGE Defendants Wells Fargo Bank, N.A., Wells Fargo Bank Northwest, N.A. (n/k/a Wells Fargo Trust Company, N.A.) (“Wells Fargo Utah”), Wells Fargo Delaware Trust Company, N.A. (“Wells Fargo Delaware”), and ATC Realty Fifteen, Inc. (“ATC,” and together, the “Wells Fargo Defendants”) have moved for a protective order pursuant to Federal Rule of Civil Procedure 26(c) to limit the scope of certain 30(b)(6) deposition topics proposed by Plaintiffs. For the reasons set forth below, the motion is granted in part and denied in part. FACTUAL BACKGROUND The Court assumes familiarity with the facts and does not repeat them here except as necessary for context. Plaintiffs are investors in three funds (the “Lifetrade Funds”). The funds invested in life insurance policies issued by United States citizens but later taken up by third-party settlement providers, which paid the insured a lump sum during their lifetime less than the value of the policy and then continued to pay the premium with the right to collect the full value of the policy upon the insured’s death. The funds closed in 2012 because of alleged mismanagement by Roy Smith, Lifetrade’s founder and CEO, and John Marcum, a consultant.
In the years before Lifetrade’s closure, the funds did not have sufficient cash to satisfy investors’ requests to redeem shares, so Lifetrade entered into a loan agreement with Defendant
Wells Fargo’s predecessor for a $500 million credit line with a repayment date of June 15, 2012. By 2012, Lifetrade had an outstanding debt of $205 million while Wells Fargo valued its portfolio of life insurance policies at $302 million. Lifetrade represented to investors that the portfolio was
worth $450 million. In March 2012, Lifetrade suspended redemptions and called a shareholder meeting to discuss the pending repayment date and expiring credit line. The Investors chose to seek long-term financing in lieu of transferring Lifetrade’s insurance policies to Wells Fargo. When Lifetrade was unable to secure the long-term financing, Wells Fargo announced it would foreclose on the debt. However, in August 2012, Wells Fargo and Lifetrade negotiated a settlement with two Lifetrade executives, Roy G. Smith and John Marcum, where Wells Fargo would acquire
Lifetrade Funds’ assets. Plaintiffs contend the settlement was unconscionable because the life insurance policies transferred under the agreement were allegedly worth more at that time than the amount of the debt extinguished. Plaintiffs also allege that the Wells Fargo Defendants aided and abetted
Smith’s and Marcum’s breaches of fiduciary duty by “playing to [Smith and Marcum’s] personal vulnerabilities . . . and orchestrating a Settlement Agreement.” 30(b)(6) DEPOSITION NOTICE
Plaintiffs served identical 30(b)(6) deposition notices on each of various Wells Fargo entities. The notices include 32 topics. The parties met and conferred on the topics but are at an impasse as to certain topics. The parties provided a helpful chart of the proposed topics and counter-proposed topics, which the Court includes as Addenda to this Opinion. The Court will utilize the Plaintiffs’ Topic Numbers and Defendants’ Counter-Proposed Topic Letters as set forth in the Addenda in this decision. DISCUSSION 1. Legal Standard Protective Orders District courts have “broad discretion to manage the manner in which discovery
proceeds.” Diamond v. 500 SLD LLC, 2022 WL 956262, at *2 (S.D.N.Y. Mar. 30, 2022) (quoting In re Subpoena Issued to Dennis Friedman, 350 F.3d 65, 69 (2d Cir. 2003)). A court may issue a protective order to safeguard a party or person “from annoyance, embarrassment, oppression, or undue burden or expense,” Fed. R. Civ. P. 26(c), “but the moving party bears the burden of establishing good cause for such a protective order.” Rekor Sys., Inc. v. Loughlin, 2022 WL 488941, at *1 (S.D.N.Y. Feb. 17, 2022) (quoting Qube Films Ltd. v. Padell, 2015 WL 109628, at *2 (S.D.N.Y.
Jan. 5, 2015)). “Ordinarily, good cause exists when a party shows that disclosure will result in a clearly defined, specific and serious injury.” In re Terrorist Attacks on Sept. 11, 2001, 454 F. Supp. 2d 220, 222 (S.D.N.Y. 2006) (internal quotation marks omitted). Ultimately, “[t]he grant and nature of protection is singularly within the discretion of the district court.” Dove v. Atl. Cap. Corp., 963 F.2d 15, 19 (2d Cir. 1992). 2. Legal Standard Rule 30(b)(6) Depositions
All 30(b)(6) deposition topics are constrained by Rule 26(b)(3)—meaning that they must seek information relevant to the claims and defenses that is proportional to the needs of the case. Further, the party seeking the deposition must describe the deposition topics with “reasonable particularity.” Fed. R. Civ. P. 30(b)(6). “Reasonable particularity” requires the topics listed to be specific as to subject area and to have discernible boundaries. Winfield v. City of New York, 2018 WL 840085, *5 (S.D.N.Y. Feb. 12, 2018).
Courts must scrutinize Rule 30(b)(6) deposition topics to ensure they are not a tool for abuse of the discovery process. Provided the topics listed in the notice meet the above criteria, the corporate defendant must produce someone familiar with the topics listed and, if one person cannot address all the topics, produce persons able to give complete, knowledgeable and binding answers on its behalf. Reilly v. NatWest Mkts. Grp. Inc., 181 F.3d 253, 268-69 (2d Cir. 1999),
superseded by statute on other grounds as recognized by Hernandez v. Jrpac Inc., 2016 WL 328493, at *35 (S.D.N.Y. June 9, 2016). If a corporation genuinely cannot provide an appropriate designee because it does not have the information, cannot reasonably obtain it from other sources, and still lacks sufficient knowledge after reviewing all available information, then its obligations under Rule 30(b)(6) cease. See, e.g., Klorczyk v. Sears, Roebuck & Co., 2015 WL 1600299, at *5 (D. Conn. Apr. 9, 2015) (quoting QBE Ins. Corp. v. Jorda Enter., Inc., 277 F.R.D. 676,
690 (S.D. Fla. 2012)); Calzaturficio S.C.A.R.P.A. s.p.a. v. Fabiano Shoe Co., Inc., 201 F.R.D. 33, 38-39 (D. Mass. 2001) (citing Fed. R. Civ. P. 30(b)(6) (requiring testimony only as to “matters known or reasonably available to the organization”) (emphasis added)). As this Court has previously recognized, the Rule challenges the propounding party to be specific so that the receiving entity can adequately prepare for a deposition. The Rule challenges the receiving company to identify people – sometimes multiple people – to answer specific topics,
and the burden of preparing for these depositions can be onerous. Because Rule 26(b)(3) restricts discovery to that which is proportional to the needs of the case, proportionality can be an important principle in limiting the burden of 30(b)(6) depositions while still providing the propounding party with information needed. Further, in light of the fact that the purpose of a Rule 30(b)(6) deposition is to “streamline the discovery process,” Winfield, 2018 WL 840085, at*5, the Court is fully within its discretion to limit 30(b)(6) topics to the extent the deposition topics do
not achieve that purpose and are unreasonably cumulative or duplicative, the information can be obtained from some other source that is more convenient, less burdensome, or less expensive, or the burden or expense of the certain deposition topics outweigh the likely benefit of requiring a company to prepare for them, considering the needs of the case, the amount in controversy, the parties' resources, the importance of the issues at stake in the action, and the importance of the
discovery in resolving the issues. See In re Weatherford Int'l Sec. Litig., 2013 WL 2355451, at *4 (S.D.N.Y. May 28, 2013). 3. The Deposition Topics The original deposition notices in this case were overbroad and contain redundant topics. Wells Fargo proposed 12 topics in lieu of 32 in an attempt at consolidating them to something more manageable. Plaintiffs have agreed to proposed topics B, C, F, G, I, and K. Therefore, Wells
Fargo must produce witnesses for these topics. To the extent the same witness can answer for each Wells Fargo entity, the witness should testify on behalf of all such entities. The following is the Court’s ruling as to the remaining proposed topics: • Topic A: In addition to this topic, when identifying the business units in each Wells Fargo entity that had dealings with Lifetrade or its principals or representatives, Wells Fargo shall produce a witness who can testify as to the relationship of the identified business units
and entities to each other and the leadership of these units and entities from 2008 through the date of the sale of the Lifetrade portfolio. • Topic D: In addition to this topic, Wells Fargo shall produce a witness who can identify the decisionmaker(s) for the decisions to (1) extend/renew the Lifetrade Loan subject to modified terms, (2) not to further extend the Lifetrade Loan, (3) issue a notice of public sale of the loan portfolio, and (4) enter into the Settlement Agreement in lieu of having a
public sale and the reasons for these decisions. To be clear, the topic as expanded does not require Wells Fargo to produce a witness regarding its business strategy with respect to the life settlement business/industry generally; rather, the witnesses should talk about the business reasons for decisions specific to management of the Lifetrade Loan and
foreclosure on that loan and settlement with Lifetrade. • Topic 9: This topic concerns Wells Fargo’s relationship with other life settlement businesses and is not focused on the claims in this case. The Court has already found that discovery into Wells Fargo’s seizure of the Berlin Capital and Q Capital life settlement portfolios is not relevant or proportional to the needs of this case, and Plaintiffs fail to offer a persuasive reason to alter this Court’s prior decision precluding such discovery. The
motion for a protective order is granted as to this topic. • Topic E: This topic overlaps with Topic D and the modifications Plaintiffs seek have been addressed in the Court’s modification to Topic D above. • Topic 13: This topic concerns the motives of Wells Fargo and its business strategy with regard to life settlements. However, this Court has already held that motive is not an element of the remaining claims against Wells Fargo. Thus, the topic is not relevant or
proportional to the needs of the case. Plaintiffs do not offer persuasive reasons to revisit this ruling. The motion for a protective order is granted as to this topic. • Topics 17: Plaintiffs have failed to explain why this topic is relevant and proportional to the needs of this case. It does not relate to an element of the claims or any defense and is therefore not an appropriate topic. The motion for a protective order is granted as to this
topic. • Topic 19: This topic as written is extraordinarily overbroad. Plaintiffs allege that Smith and Marcum violated their fiduciary duties to Lifetrade in specific ways. Plaintiffs could have tailored a topic to ask whether Wells Fargo was aware of specific conduct of Smith and
Marcum that Plaintiffs contend constituted the alleged breach of fiduciary duty. However, they did not do this. Plaintiffs can ask fact witnesses for Wells Fargo questions about what they knew about Smith and Marcum’s alleged conduct that forms the basis for the allegations of breach of fiduciary duty. The motion for a protective order is granted as to this topic. • Topic H: Plaintiffs’ objections to this topic as narrowed by Wells Fargo have been
addressed by the Court in Topic D, as modified by the Court. • Topic 27: This topic concerns a post-litigation investigation by Wells Fargo into the allegations of the complaint, which is primarily work product and privileged. Wells Fargo’s investigation itself is not relevant to the claims and defenses. Rather, the underlying facts about the loan are what is relevant. Further, Plaintiffs merely state that this topic is proportional to the needs of the case without stating why. Thus, their opposition to the
motion is unpersuasive. The motion for a protective order is granted as to this topic. • Topic J: In addition to the topic, Wells Fargo shall provide a witness to testify about its knowledge of any offers to purchase the Lifetrade Portfolio made by Perella Weinberg Partners or other third-party during the servicing of the loan and prior to the 2012 settlement and, if any such offers were made, what the offers were, and whether those
offers would have been sufficient to cover the outstanding loan amount and the reasons any offers were rejected (if Wells Fargo knows). The additional information is relevant to the issue of foreclosure and settlement and whether Lifetrade management had other options other than to settle with Wells Fargo. • Topic L and Topics 31 and 32: The way in which Wells Fargo has limited this topic ignores
Plaintiff’s legitimate interest in understanding the factual basis for Wells Fargo’s in pari delicto defense. Plaintiffs are entitled to learn what benefits, if any, Wells Fargo believes the settlement conferred on the Lifetrade Funds, consistent with the Court’s decision denying Wells Fargo’s motion to dismiss based on the defense of in pari delicto. Accordingly, Wells Fargo shall produce a witness to testify on this subject. To be clear, the questions on this topic must focus on the facts and should not ask for a legal conclusion.
Except for this defense, Plaintiffs do not specify what they want to understand about any other affirmative defense raised by Wells Fargo as set forth in Topic 32. Thus, Topic 32 is overbroad and vague. CONCLUSION For the reasons set forth above, Wells Fargo’s motion is granted in part and denied in part. The deposition topics proposed by Wells Fargo as modified by the Court above shall be the topics on which the 30(b)(6) depositions shall proceed. To the extent the same witness can answer for each Wells Fargo entity, the witness should testify on behalf of all such entities. Dated: May 4, 2023 New York, New York So ordered, bhai, H Fete KATHARINE H. PARKER United States Magistrate Judge
ADDENDA In re Lifetrade Litigation, 1:17-cv-02987 (JPO) (KHP)
30(b)(6) Topics and Counter-Proposed Topics for the Depositions of Wells Fargo Bank, N.A., ATC Realty Fifteen, Inc., and Wells Fargo Bank Northwest, N.A. (n/k/a Wells Fargo Trust Company, N.A.)
Topics in Plaintiffs’ 30(b)(6) Deposition Defendants’ Counter-Proposed Topics Notices Topic 1: Your organizational and reporting structure, and the organizational structures of the other Wells Fargo Defendants, from 2008 to the date of the commencement of this Action.
Topic 2: The identities of all persons
employed by or affiliated with You or Wells
Fargo who participated in any meetings or business dealings, at any time, concerning Smith, Marcum, any Lifetrade Entity, the Topic A: Wells Fargo Bank, N.A., ATC, and Lifetrade Loan, the Lifetrade Portfolio of Wells Fargo Utah will designate one or more Policies, and/or any Lifetrade Underwriter. witnesses to provide non-privileged testimony identifying the business units of, Topic 22 (Dup’e of 2, 8, 21): Your internal and the individuals employed by or affiliated meetings and communications and internal with, each such Wells Fargo Defendant who meetings and communications within Wells had dealings with Lifetrade or its principals Fargo or any division thereof, respecting the or representatives concerning the Lifetrade potential seizure of the Lifetrade Portfolio of Loan, the Settlement Agreement, or the Policies as repayment of the outstanding debt Policies during the relevant time period. at any time.
Topic 23 (Dup’e of 2, 8, 21): Meetings and/or communications concerning the Lifetrade Funds and/or the Lifetrade Portfolio of Policies between or among You, Wells Fargo and any other person or entity concerning Wells Fargo’s decision to buy, sell, transfer, use, or foreclose on the Lifetrade Fund’s assets. Topic 3 (Dup’e of 4): Your or Wells Fargo’s business unit or division that acquired and managed the Lifetrade Portfolio of Policies pursuant to the Settlement Agreement or 2012.
Topic 4: The administration and/or
management by You or Wells Fargo of the Topic B: Well Fargo Bank, N.A., and ATC Lifetrade Portfolio of Policies, including will designate one or more witnesses to identification of each policy, dates of provide non-privileged testimony concerning maturity of each policy, dates and amounts of the following subjects that post-date the premiums paid by Wells Fargo for each Settlement Agreement: (a) payment of policy, and dates and amounts of proceeds or premiums; (b) receipt of death benefits, (c) other benefits received by Wells Fargo for readily quantifiable costs associated with each policy within the Portfolio, from the management of the Policies; (d) the sale of the time Wells Fargo acquired the Portfolio in Policies; (e) proceeds from the sale of the 2012 until the time Wells Fargo sold the policies; (f) the business units of, and Portfolio or any portion thereof. individuals employed by or affiliated with
Topic 5: The sale of the Lifetrade Portfolio Well Fargo Bank, N.A., and ATC involved with the aforementioned subjects; and (g) of Policies or any portion thereof by You or documents concerning the aforementioned any Wells Fargo entity, including the subjects each such Wells Faro Defendant proceeds Wells Fargo received for the sale of already identified by Bates range for each life insurance policy comprising or Plaintiffs. within the Lifetrade Portfolio of Policies.
Topic 7: The review or valuation of the performance of the Lifetrade Portfolio by You, Wells Fargo, or any third party after Wells Fargo’s 2012 acquisition of the Portfolio. Topic 6: The valuation of the Lifetrade Funds, and assets comprising those Funds, by Topic C: Well Fargo Bank, N.A., and ATC You, Wells Fargo, or any third party at any will designate one or more witnesses to time. provide non-privileged testimony concerning Topic 20 (Dup’e of 6): Lifetrade’s periodic the value of the Policies during the relevant Net Asset Value (“NAV”) and/or reporting of time period. the performance of the Lifetrade Funds. Topic 8: The decision by You or any Wells Fargo entity to foreclose on or otherwise acquire the Lifetrade Portfolio of Policies. Topic 11 (Dup’e of 8): The repayment by Lifetrade of the Lifetrade Loan including the timing and amount of each periodic payment made by Lifetrade from 2008 through August
2012. Topic 15 (Dup’e of 8, 10): Meetings and/or
communications concerning the subject of
foreclosing on the Lifetrade Loan at any time,
including meetings/communications concerning decisions to extend the maturity date of the loan, or to refrain from such extensions. Topic 22 (Dup’e of 2, 8, 21): Your internal meetings and communications and internal meetings and communications within Wells Fargo or any division thereof, respecting the potential seizure of the Lifetrade Portfolio of Topic D: Wells Fargo Bank, N.A. will Policies as repayment of the outstanding debt at designate one or more witnesses to any time. provide non-privileged testimony Topic 23 (Dup’e of 2, 8, 21): Meetings and/or concerning Wells Fargo Bank, N.A.’s communications concerning the Lifetrade Funds decision in 2012 to: (a) not further extend and/or the Lifetrade Portfolio of Policies between the Lifetrade Loan; (b) issue a notice of or among You, Wells Fargo and any other person public sale dated August 8, 2012; and (c) or entity concerning Wells Fargo’s decision to enter into the Settlement Agreement. buy, sell, transfer, use, or foreclose on the Lifetrade Fund’s assets. Topic 24 (Dup’e of 8, 10, 21): The original, executed and/or draft versions, including amendments and modifications of: (a) The 2008 agreement and subsequent extensions for the $500M debt facility for Lifetrade, including the 2010 reduction and any other modification of the debt facility; (b) The 2010 Assignment and Assumption Agreement; (c) The 2010 Variable Funding Note; (d) The Nondisclosure Agreement related to Wells Fargo’s acquisition of the Lifetrade Portfolio; (e) The March 25, 2011 reorganization of the Lifetrade Fund. BV involving Lifetrade Life Settlements Ltd.; (f) The March 28, 2011 Loan and Security Agreement; (g) The August 8, 2012 Foreclosure Notice; (h) The Settlement Agreement of August 14, 2012; and (i) The Bill of Sale concerning the Lifetrade Funds. Topic 9: The decision by You or any Wells N/A Fargo entity to foreclose on any loan or debt facility between Wells Fargo and any life The Wells Fargo Defendants object to this settlement business, including but not limited to topic and will not be producing a witness Berlin Capital, Inc. and Q Capital. for any of the Wells Fargo Defendants. See Memorandum of Law in Supp. of Mtn. for Protective Order at Part I.A. Topic 10: Wells Fargo’s acquisition of the Lifetrade Loan from Wachovia, and each and every subsequent loan, debt facility or other agreement, and any amendment, and/or modification thereof, that You or any Wells
Fargo entity offered to or entered into with any
Lifetrade Entity, or any of Lifetrade’s managers,
including Smith and/or Marcum.
Topic 12 (Dup’e of 10): The administration of
the Lifetrade Loan or debt facility from inception to foreclosure, including but not limited to: (a) decisions to renew the facility; (b) the credit limit or amount of the loan at renewal; (c) the interest rate charged for the loan or debt facility; and (d) the fees charged in association with such loan or Topic E: Wells Fargo Bank, N.A. will debt facility. designate one or more witnesses to
Topic 15 (Dup’e of 8, 10): Meetings and/or provide non-privileged testimony concerning Wells Fargo Bank, N.A.’s communications concerning the subject of management of, and extensions or foreclosing on the Lifetrade Loan at any time, modifications to, the Lifetrade Loan including meetings/communications concerning during the relevant time period. decisions to extend the maturity date of the loan, or to refrain from such extensions.
Topic 24 (Dup’e of 8, 10, 21): The original, executed and/or draft versions, including amendments and modifications of: (a) The 2008 agreement and subsequent extensions for the $500M debt facility for Lifetrade, including the 2010 reduction and any other modification of the debt facility; (b) The 2010 Assignment and Assumption Agreement; (c) The 2010 Variable Funding Note; (d) The Nondisclosure Agreement related to Wells Fargo’s acquisition of the Lifetrade Portfolio; (e) The March 25, 2011 reorganization of the Lifetrade Fund. BV involving Lifetrade Life Settlements Ltd.; (f) The March 28, 2011 Loan and Security Agreement; (g) The August 8, 2012 Foreclosure Notice; (h) The Settlement Agreement of August 14, 2012; and (i) The Bill of Sale concerning the Lifetrade Funds. Topic 13: Your or Wells Fargo’s position from N/A 2008 through 2012 concerning Wells Fargo investing in life settlement transactions generally, The Wells Fargo Defendants object to this and/or in lending to businesses that invested in topic and will not be producing a witness life settlements. for any of the Wells Fargo Defendants. See Memorandum of Law in Supp. of Mtn. for Protective Order at Part I.A. Topic 16: The transfer of ownership of the Topic F: Wells Fargo Utah will Portfolio of Policies from the Lifetrade Fund designate one or more witnesses to B.V. to Lifetrade Life Settlements Limited. provide non-privileged testimony concerning Well Fargo Utah’s role during the relevant time period as Managing Trustee under the Trust Agreement dated August 13, 2010 and any subsequent amendments thereto, including Wells Fargo Utah’s role in connection with the execution of the Settlement Agreement by LT Opportunity Trust. Topic 17: The issuance of debt securities from N/A Lifetrade Life Settlements Limited to LT Investments, Inc. The Wells Fargo Defendants object to this topic and will not be producing a witness for any of the Wells Fargo Defendants. See Memorandum of Law in Supp. of Mtn. for Protective Order at Part I.B. Topic 18: You or any Wells Fargo Entity’s Topic G: Wells Fargo Bank, N.A. will activities as Custodian of the Lifetrade Loan. designate one or more witnesses to provide non-privileged testimony concerning its role as Custodian in connection with the Lifetrade Loan. Topic 19: Information acquired by You or any N/A Wells Fargo Entity respecting any potential bribes, commissions, money laundering, theft, The Wells Fargo Defendants object to this embezzlement or misappropriation of money or topic and will not be producing a witness assets by Smith, Marcum, or any Lifetrade Entity, for any of the Wells Fargo Defendants. and any meetings between or among You and See Memorandum of Law in Supp. of Mtn. Wells Fargo on these subjects. for Protective Order at Part I.B. Topic 21: The negotiation, drafting and signing of the 2012 Settlement Agreement, and each and every provision of the Settlement Agreement including but not limited to the provision prohibiting Lifetrade Management from revealing
Wells Fargo’s motivations to Lifetrade
shareholders or investors.
Topic 22 (Dup’e of 2, 8, 21): Your internal
meetings and communications and internal meetings and communications within Wells Fargo or any division thereof, respecting the potential seizure of the Lifetrade Portfolio of Policies as repayment of the outstanding debt at any time.
Topic 23 (Dup’e of 2, 8, 21 ): Meetings and/or communications concerning the Lifetrade Funds and/or the Lifetrade Portfolio of Policies between or among You, Wells Fargo and any other person Topic H: Wells Fargo Bank, N.A., ATC, or entity concerning Wells Fargo’s decision to and Wells Fargo Utah will designate one buy, sell, transfer, use, or foreclose on the or more witnesses to provide non- Lifetrade Fund’s assets. privileged testimony concerning the
Topic 24 (Dup’e of 8, 10, 21): The original, n Ae gg ro et ei mat eio nn t. and terms of the Settlement executed and/or draft versions, including amendments and modifications of: (a) The 2008 agreement and subsequent extensions for the $500M debt facility for Lifetrade, including the 2010 reduction and any other modification of the debt facility; (b) The 2010 Assignment and Assumption Agreement; (c) The 2010 Variable Funding Note; (d) The Nondisclosure Agreement related to Wells Fargo’s acquisition of the Lifetrade Portfolio; (e) The March 25, 2011 reorganization of the Lifetrade Fund. BV involving Lifetrade Life Settlements Ltd.; (f) The March 28, 2011 Loan and Security Agreement; (g) The August 8, 2012 Foreclosure Notice; (h) The Settlement Agreement of August 14, 2012; and (i) The Bill of Sale concerning the Lifetrade Funds. Topic 26: Your document retention policies Topic I: One or more witnesses will be relevant to this action. designated by the relevant Wells Fargo Defendant to provide non-privileged testimony concerning how certain documents (that may be reasonably identified by Plaintiffs in their opposition to this motion) were maintained in the normal course of business. Topic 27: Internal investigations by You or any N/A Wells Fargo entity concerning Plaintiff’s allegations. The Wells Fargo Defendants object to this topic and will not be producing a witness for any of the Wells Fargo Defendants. See Memorandum of Law in Supp. of Mtn. for Protective Order at Part I.B. Topic 14 (Dup’e of 28, 29): Offers to purchase the Lifetrade Portfolio made by Perella Weinberg Partners or any other third party, prior to the 2012 Settlement Agreement, and Your or Wells
Fargo’s responses to such offers. Topic J: Wells Fargo Bank, N.A. will
Topic 28: Meetings and/or correspondence designate one or more witnesses to provide non-privileged testimony between or among You and/or any Wells Fargo concerning its knowledge of Lifetrade’s Entity regarding refinancing of the Lifetrade loan efforts since 2011 to refinance the at any time before or after the Settlement Lifetrade Loan. ATC will designate one Agreement of 2012. Topic 29: Meetings and/or correspondence o pr r im vio ler ge e w d i tt en se ts imse os nto y p coro nv ci ed re n in no gn i- t s between or among You and/or any Wells Fargo knowledge of Lifetrade’s efforts to Entity and any third party, including but not reacquire the Policies after the Settlement limited to: Smith, Marcum, anyone affiliated with Agreement. Lifetrade, any Plaintiff, investor or broker, any bank or lending institution, or anyone else regarding refinancing of the Lifetrade Loan at any time before or after the Settlement Agreement of 2012. Topic 30: Meetings and/or correspondence with Topic K: Wells Fargo Bank, N.A. and Smith or anyone else affiliated with any Lifetrade ATC will designate one or more witnesses Entity, and You or Wells Fargo after the to provide non-privileged testimony execution of the Settlement Agreement in August concerning communications generally 2012. with Lifetrade or any of its principals or representatives after the execution of the Settlement Agreement. Topic 31: Facts on which you will rely in Topic L: Without limitation to every fact support of your in pari delicto defense. the Wells Fargo Defendants may rely upon in connection with the in pari delicto defense, Wells Fargo Bank, N.A. will designate one or more witnesses to testify about (i) the debt extinguished by the Settlement Agreement; (ii) the Option to Purchase under §5.1 of the Settlement Agreement; (iii) the Net Proceeds under §11.1 of the Settlement Agreement; and (iv) Lifetrade’s efforts to reacquire the Policies after the Settlement Agreement. Topic 32: Facts on which you will rely in N/A support of any affirmative defense. The Wells Fargo Defendants object to this topic and will not be producing a witness for any of the Wells Fargo Defendants. See Memorandum of Law in Supp. of Mtn. for Protective Order at Part I.C. Annex A
To avoid undue repetition in the main table above, Plaintiffs’ Topic 25, which is duplicative of as many as 7 other topics, is listed separately in the below table in this Annex A.
Topics in Plaintiffs’ 30(b)(6) Deposition Duplicative of Topic(s) Notices Topic 25: Meetings and/or communications Duplicative of Plaintiffs’ Topics 2, 6, 7, 8, concerning the Lifetrade Funds, Lifetrade 10, 21, and 28 as to Wells Fargo Bank, N.A. Entities, Lifetrade Loan, and/or Lifetrade and thus captured by defendants’ counter- Portfolio of Policies between or among You, proposed Topics A, B, C, D, E, H and J. Wells Fargo, and any other person or entity, including but not limited to: (a) Wachovia, or Duplicative of Plaintiffs’ Topics 2, 6, 7, 21, any person associated with Wachovia; (b) Roy and 28 as to ATC and thus captured by Smith, or any person associated with Roy defendants’ counter-proposed Topics A, B, C Smith; (c) John Marcum, or any person H and J. associated with John Marcum; (d) S&P, or any person associated with S&P; (e) Milliman, Duplicative of Plaintiffs’ Topics 2 and 21 as Inc., or any person associated with Milliman, to Wells Fargo Utah and thus captured by Inc.; (f) AVS, or any person associated with defendants’ counter-proposed Topic A and AVS; (g) ITM 21st Services or any person H. associated with ITM 21st Services; (h) Any Lifetrade Entity; (i) KPMG; (j) HBM; (k) Any Lifetrade Underwriter; (l) Any Plaintiff or other investor; (m) Any broker.